Calypso Biotech

Calypso Biotech is the third spin-off company from the EPP Fund. The company is developing an anti IL-15 antibody against immune disorders, currently evaluated in celiac disease and eosinophilic esophagitis. Calypso Biotech is based in Geneva, Switzerland and Amsterdam, Netherlands.